FeesSafety
Pluang+

First US Bancshares reports Q3 net income of $2M, up 11.8% from Q2, with improved loan quality and net interest margin.

Company Fundamentals
28 Oct 2026, 23:15 WIB
PRNewsWire
View Source
Bullish
First US Bancshares reports Q3 net income of $2M, up 11.8% from Q2, with improved loan quality and net interest margin.

First US Bancshares posted a net income of $2.0 million for Q3 2026, an 11.8% increase from Q2, driven by higher net interest margin and lower credit losses. Total loans slightly decreased due to expected project payoffs, while indirect consumer loans grew. The bank maintained strong capital ratios and declared a consistent dividend of $0.07 per share. Management remains focused on disciplined credit quality and expanding commercial lending relationships amid stable liquidity and improved asset quality.

First US Bancshares, Inc.'s third quarter and year-to-date 2026 results provide context for readers. For those following the Financials sector, Pluang data as of Oct 29, 2026 03:01 WIB shows 85 of 142 US financial stocks rose while 56 fell. Deutsche Bank AG (DB) gained 4.27% to USD 33.49 with a 63% buy order activity, CleanSpark Inc (CLSK) rose 4.21% to USD 8.54 also with 63% buy activity, contrasting Robinhood Markets, Inc. (HOOD) which dropped 4.20% to USD 90.59 with 59% buy activity. Typical hold times vary from 23 to 81 days among these assets.

More News

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market to reach $8.04B by 2032, driven by cafe culture and specialty coffee growth.

China's coffee market is projected to grow from $5.8 billion in 2026 to $8.04 billion by 2032, at a CAGR of 5.54%. Growth is fueled by expanding chain cafes, specialty coffee methods like cold brew, and rising homegrown brands. However, rising coffee...

Market News
Neutral
23 minutes ago
FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

FDA grants orphan drug status to sovleplenib for rare autoimmune disease ITP treatment

HUTCHMED announced that the US FDA has granted orphan drug designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder causing low platelet counts and bleeding risks. This status provides benefits like 7 ...

Market News
Bullish
23 minutes ago
LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED hosts global media test drive showcasing advanced tech and luxury in new LLounge and Stormax models.

LUXEED held a global media test drive event at Chery's International Headquarters in Vu Hồ, featuring the luxury MPV LLounge and the high-performance Stormax SUV. Media representatives and influencers from UAE, Thailand, and Indonesia experienced a 1...

Market News
Bullish
23 minutes ago
Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Law firm investigates NVE Corporation over sharp Q2 revenue drop and stock plunge.

Kirby McInerney LLP is investigating NVE Corporation for possible violations of federal securities laws after the company reported a 47% revenue decline and a 33.7% stock price drop following its Q2 fiscal 2027 results. The revenue fall was attribute...

Market News
Bearish
2 hours ago
Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology warned by Nasdaq for falling below $1 minimum bid price, given 180 days to comply.

Fort Technology received a notification from Nasdaq on October 13, 2026, stating it failed to meet the minimum bid price requirement of $1.00 per share over the past 30 days. The company has 180 days, until April 12, 2027, to restore its share price ...

Market News
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App